Nashville, Tennessee Clinical Trials

A listing of Nashville, Tennessee clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

etoposide
cancer
maintenance therapy
lung cancer
atezolizumab
SARAH CANNON RESEARCH INST.; Tennessee Oncology, PLLC
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +146 other locations
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

cancer therapy
maintenance therapy
cancer
chemoradiotherapy
measurable disease
Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +15 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …

Vanderbilt University Medical Center
 (2.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +30 other locations
Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration

This study will evaluate which procedure is the best for patients referred for biopsy of a lung nodule (growth in the lung) meeting the size and location requirements of the protocol. Two different procedures are available for lung nodule biopsy: a computed tomography guided biopsy ("CT-guided biopsy") which consists of …

Vanderbilt-Ingram Cancer Center
 (2.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

This study is a multi-center, open-label, dose escalation study of RLY-1971 in subjects with advanced or metastatic solid tumors.

solid tumor
solid tumour
hair thinning
neuropathy
metastatic malignant solid tumor
SCRI-Nashville/Tennessee Oncology
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …

Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
At-Risk for Type 1 Diabetes Extension Study

This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …

diabetes
type 1 diabetes mellitus
teplizumab
Clinical Site
 (2.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +4 other locations
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.

hepatitis
non-small cell lung cancer
cancer
lung cancer
atezolizumab
Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

This is a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181 administered alone and in combination with anti-PD-(L)1 therapy in adult patients with locally advanced or metastatic solid tumors. The study is divided into …

progressive disease
non-small cell lung cancer
lymphoma
measurable disease
solid neoplasm
Tennessee Oncology, Sarah Cannon Research Institute
 (0.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors

A first-in-human (FIH) study using SBT6050 in HER2 expressing advanced malignancies

cancer
solid tumor
pembrolizumab
solid tumour
measurable disease
Investigative Site
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations